Effects of morphine, physostigmine and raphe nuclei stimulation on 5-hydroxytryptamine release from the cerebral cortex of the cat.
1. The release of 5-hydroxytryptamine (5-HT) from the cerebral cortex and caudate nucleus of brainstem-transected cats and from the cerebral cortex of rats anaesthetized with urethane was determined by radioenzymatic and biological assay. 2. The stimulation of nucleus linearis intermedius of raphe doubles the basal 5-HT release in the caudate nucleus and increases it 3 fold in the cerebral cortex. The effects of the electrical stimulation of the raphe are potentiated by chlorimipramine. 3. Brain 5-HT release is greatly increased by morphine hydrochloride (6 mg/kg i.v.) and by physostigmine (100 microgram/kg i.v.), but not by DL-DOPA (50 mg/kg i.v.). 4. It is suggested that the 5-HT releasing action of physostigmine can contribute to some of its pharmacological effects such as the analgesic effect so far attributed exclusively to its indirect cholinomimetic activity. 5. The 5-HT releasing action of physostigmine seems unrelated to its anticholinesterase activity.
D000818:Animals; D001933:Brain Stem / Q000502:physiology*; D002415:Cats; D002540:Cerebral Cortex / Q000187:drug effects / Q000378:metabolism*; D004295:Dihydroxyphenylalanine / Q000494:pharmacology; D004558:Electric Stimulation; D004569:Electroencephalography; D005260:Female; D007980:Levodopa / Q000494:pharmacology; D008297:Male; D009020:Morphine / Q000494:pharmacology*; D010830:Physostigmine / Q000494:pharmacology*; D011903:Raphe Nuclei / Q000502:physiology*; D051381:Rats; D012701:Serotonin / Q000378:metabolism*; D013045:Species Specificity
D012701:Serotonin; D007980:Levodopa; D004295:Dihydroxyphenylalanine; D009020:Morphine; D010830:Physostigmine